Literature DB >> 26202754

Diagnostic role of radiolabelled choline PET or PET/CT in hepatocellular carcinoma: a systematic review and meta-analysis.

Francesco Bertagna1, Mattia Bertoli2, Giovanni Bosio2, Giorgio Biasiotto3, Ramin Sadeghi4, Raffaele Giubbini2, Giorgio Treglia5.   

Abstract

The role of fluorine-18-fluorodeoxygluose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in hepatocellular carcinoma (HCC) has not been firmly established yet and its sensitivity has been reported to be in the range of 40-60 %. Because of this relatively low sensitivity alternative tracers have been proposed. The aim of our review is to analyse the literature data on the diagnostic role of (18)F/(11)C-choline PET/CT in the evaluation of HCC. A comprehensive computer literature search of PubMed/MEDLINE, Embase and Scopus databases was conducted to find relevant published articles about the role of whole-body (18)F-choline or (11)C-choline PET or PET/CT in patients with HCC. Furthermore, a meta-analysis about the detection rate of this method in HCC was performed. Six articles were included in this systematic review and discussed. The meta-analysis of five out of six articles showed a DR of 84 % (95 % CI 79-89 %). The DR increased when poorly differentiated HCC was excluded from the analysis. Radiolabelled choline PET or PET/CT could be a valuable tool in detecting HCC and it is better than (18)F-FDG PET/CT, especially in well to moderately differentiated lesions; on the other hand, poorly differentiated and higher-stage HCC could be better evaluated with (18)F-FDG and dual tracer imaging should be considered and could be potentially useful to increase accuracy.

Entities:  

Keywords:  11C-choline; 18F-choline; HCC; Hepatocellular carcinoma; PET/CT

Year:  2014        PMID: 26202754     DOI: 10.1007/s12072-014-9566-0

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  44 in total

1.  Blood metabolism of [methyl-11C]choline; implications for in vivo imaging with positron emission tomography.

Authors:  A Roivainen; S Forsback; T Grönroos; P Lehikoinen; M Kähkönen; E Sutinen; H Minn
Journal:  Eur J Nucl Med       Date:  2000-01

2.  [Positron emission tomography with fluorine-18-fluorodeoxyglucose is useful for predicting the prognosis of patients with hepatocellular carcinoma].

Authors:  Yun Ho Kong; Chul Ju Han; Sang Dae Lee; Wee Sik Sohn; Min Jae Kim; Seung Seog Ki; Jin Kim; Sook Hyang Jeong; You Cheoul Kim; Jhin Oh Lee; Gi Jeong Cheon; Chang Woon Choi; Sang Moo Lim
Journal:  Korean J Hepatol       Date:  2004-12

3.  PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT.

Authors:  Jean-Noël Talbot; Fabrice Gutman; Laetitia Fartoux; Jean-Didier Grange; Nathalie Ganne; Khaldoun Kerrou; Dany Grahek; Françoise Montravers; Raoul Poupon; Olivier Rosmorduc
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-27       Impact factor: 9.236

4.  Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma.

Authors:  S Shiomi; S Nishiguchi; H Ishizu; Y Iwata; N Sasaki; A Tamori; D Habu; T Takeda; S Kubo; H Ochi
Journal:  Am J Gastroenterol       Date:  2001-06       Impact factor: 10.864

Review 5.  PET with (18)F-labelled choline-based tracers for tumour imaging: a review of the literature.

Authors:  Koen Mertens; Dominique Slaets; Bieke Lambert; Marjan Acou; Filip De Vos; Ingeborg Goethals
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-11       Impact factor: 9.236

6.  The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma.

Authors:  L James Wudel; Dominique Delbeke; David Morris; Michael Rice; Mary Kay Washington; Yu Shyr; C Wright Pinson; William C Chapman
Journal:  Am Surg       Date:  2003-02       Impact factor: 0.688

7.  Fluoromethylcholine PET in recurrent multifocal hepatoma.

Authors:  N P Lenzo; J Anderson; A Campbell; L Morandeau; T R De Grado
Journal:  Australas Radiol       Date:  2007-12

8.  11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspective.

Authors:  Tan To Cheung; Chi Lai Ho; Chung Mau Lo; Sirong Chen; See Ching Chan; Kenneth S H Chok; James Y Fung; Albert Chi Yan Chan; William Sharr; Thomas Yau; Ronnie T P Poon; Sheung Tat Fan
Journal:  J Nucl Med       Date:  2013-01-15       Impact factor: 10.057

9.  Role of ¹⁸F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma.

Authors:  Vineet Pant; Ishita B Sen; Arvinder S Soin
Journal:  Nucl Med Commun       Date:  2013-08       Impact factor: 1.690

10.  PET imaging of hepatocellular carcinoma with 2-deoxy-2[18F]fluoro-D-glucose, 6-deoxy-6[18F] fluoro-D-glucose, [1-11C]-acetate and [N-methyl-11C]-choline.

Authors:  N Salem; Y Kuang; F Wang; G T Maclennan; Z Lee
Journal:  Q J Nucl Med Mol Imaging       Date:  2008-11-28       Impact factor: 2.346

View more
  13 in total

1.  Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy.

Authors:  Michael C Wallace; Kenny Sek; Roslyn J Francis; Shaun Samuelson; John Ferguson; Jonathan Tibballs; Ali Asad; David B Preen; Gerry MacQuillan; George Garas; Leon A Adams; Gary P Jeffrey
Journal:  Dig Dis Sci       Date:  2019-08-22       Impact factor: 3.199

2.  Validation of R-2-[18F]Fluoropropionic Acid as a Potential Tracer for PET Imaging of Liver Cancer.

Authors:  Zhanwen Zhang; Shaoyu Liu; Hui Ma; Dahong Nie; Fuhua Wen; Jing Zhao; Aixia Sun; Gongjun Yuan; Shu Su; Xianhong Xiang; Ping Hu; Ganghua Tang
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

3.  Metformin Promotes 2-Deoxy-2-[18F]Fluoro-D-Glucose Uptake in Hepatocellular Carcinoma Cells Through FoxO1-Mediated Downregulation of Glucose-6-Phosphatase.

Authors:  Zhengjie Wang; Fei Kang; Yongheng Gao; Yi Liu; Xiaolong Xu; Xiaowei Ma; Wenhui Ma; Weidong Yang; Jing Wang
Journal:  Mol Imaging Biol       Date:  2018-06       Impact factor: 3.488

4.  Local-Regional Treatment of Hepatocellular Carcinoma: A Primer for Radiologists.

Authors:  Natally Horvat; Ana I de Oliveira; Brunna Clemente de Oliveira; Jose A B Araujo-Filho; Maria El Homsi; Ahmed Elsakka; Raazi Bajwa; Guilherme L P Martins; Khaled M Elsayes; Marcos R Menezes
Journal:  Radiographics       Date:  2022-10       Impact factor: 6.312

5.  Diagnostic value of combining ¹¹C-choline and ¹⁸F-FDG PET/CT in hepatocellular carcinoma.

Authors:  Maria-Angéla Castilla-Lièvre; Dominique Franco; Philippe Gervais; Bertrand Kuhnast; Hélène Agostini; Lysiane Marthey; Serge Désarnaud; Badia-Ourkia Helal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-18       Impact factor: 9.236

6.  Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).

Authors:  Jian Zhou; Huichuan Sun; Zheng Wang; Wenming Cong; Jianhua Wang; Mengsu Zeng; Weiping Zhou; Ping Bie; Lianxin Liu; Tianfu Wen; Guohong Han; Maoqiang Wang; Ruibao Liu; Ligong Lu; Zhengang Ren; Minshan Chen; Zhaochong Zeng; Ping Liang; Changhong Liang; Min Chen; Fuhua Yan; Wenping Wang; Yuan Ji; Jingping Yun; Dingfang Cai; Yongjun Chen; Wenwu Cheng; Shuqun Cheng; Chaoliu Dai; Wenzhi Guo; Baojin Hua; Xiaowu Huang; Weidong Jia; Yaming Li; Yexiong Li; Jun Liang; Tianshu Liu; Guoyue Lv; Yilei Mao; Tao Peng; Weixin Ren; Hongcheng Shi; Guoming Shi; Kaishan Tao; Wentao Wang; Xiaoying Wang; Zhiming Wang; Bangde Xiang; Baocai Xing; Jianming Xu; Jiamei Yang; Jianyong Yang; Yefa Yang; Yunke Yang; Shenglong Ye; Zhengyu Yin; Bixiang Zhang; Boheng Zhang; Leida Zhang; Shuijun Zhang; Ti Zhang; Yongfu Zhao; Honggang Zheng; Jiye Zhu; Kangshun Zhu; Rong Liu; Yinghong Shi; Yongsheng Xiao; Zhi Dai; Gaojun Teng; Jianqiang Cai; Weilin Wang; Xiujun Cai; Qiang Li; Feng Shen; Shukui Qin; Jiahong Dong; Jia Fan
Journal:  Liver Cancer       Date:  2020-11-11       Impact factor: 11.740

7.  Long non-coding RNA Igf2as controls hepatocellular carcinoma progression through the ERK/MAPK signaling pathway.

Authors:  Han Bao; Chun-Guang Guo; Peng-Cheng Qiu; Xin-Lei Zhang; Qi Dong; Yu-Kun Wang
Journal:  Oncol Lett       Date:  2017-06-30       Impact factor: 2.967

8.  Predicting tumor recurrence using metabolic indices of 18F-FDG PET/CT prior to orthotopic liver transplantationfor hepatocellular carcinoma.

Authors:  Enci Ding; Dongyan Lu; Lijuan Wei; Xuemin Feng; Jie Shen; Wengui Xu
Journal:  Oncol Lett       Date:  2020-05-28       Impact factor: 2.967

Review 9.  State of the art in magnetic resonance imaging of hepatocellular carcinoma.

Authors:  Natally Horvat; Serena Monti; Brunna Clemente Oliveira; Camila Carlos Tavares Rocha; Romina Grazia Giancipoli; Lorenzo Mannelli
Journal:  Radiol Oncol       Date:  2018-11-26       Impact factor: 2.991

10.  A Case of Well-differentiated Hepatocellular Carcinoma Identified on Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography.

Authors:  Hian Liang Huang; Tracy Jie Zhen Loh; Pierce Kah Hoe Chow
Journal:  World J Nucl Med       Date:  2018 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.